Pancreas transplantation is a definitive surgical therapy designed to restore normal glucose homeostasis in individuals with severe pancreatic endocrine failure. Managed under the medical specialty of transplant surgery, the procedure involves grafting a deceased donor pancreas—often combined with a donor kidney—into the recipient's lower abdomen. The primary physiological mechanism is the restoration of functional pancreatic beta cells within the islets of Langerhans, which automatically sense blood glucose concentrations and secrete insulin and glucagon in real-time. Successful transplantation establishes normoglycemia, prevents recurrent life-threatening hypoglycemic episodes, and halts or slows the progression of secondary diabetic complications such as neuropathy, retinopathy, and nephropathy.

Pancreas transplantation is performed under general anesthesia. The surgical team makes a midline lower abdominal incision. The donor pancreas, often procured along with the donor duodenum, is prepared on ice. The graft blood vessels—the donor portal vein and donor iliac arterial Y-graft (connected to the donor superior mesenteric and splenic arteries)—are anastomosed to the recipient's common or external iliac artery and vein. Once vascular clamps are removed and blood flow is re-established (reperfusion), the graft turns pink and begins secreting insulin immediately. The exocrine secretions of the donor pancreas (pancreatic juice containing digestive enzymes) must be drained; this is achieved by performing an enteric anastomosis (connecting the donor duodenal segment to the recipient's small intestine) or, less commonly, a bladder anastomosis (connecting the donor duodenal segment to the recipient's urinary bladder). A surgical drain is placed, and the abdominal wall is closed in layers.

Clinical outcomes documented across international transplant registries demonstrate substantial microvascular, metabolic, and quality-of-life benefits for successful pancreas transplant recipients:

• Complete Insulin Independence: Over 90% of successful graft recipients achieve complete freedom from daily subcutaneous insulin injections and continuous glucose monitoring.
• Elimination of Severe Hypoglycemia: Restoration of glucagon counter-regulation and dynamic insulin secretion completely prevents severe hypoglycemic events and restores hypoglycemia awareness.
• Stabilization of Secondary Complications: Long-term normoglycemia halts the progression of diabetic neuropathy, stabilizes diabetic retinopathy, and protects against recurrent diabetic nephropathy in transplanted kidneys.
• Cardiovascular Protection: Re-establishing metabolic control improves lipid profiles, reduces arterial stiffness, and decreases long-term cardiovascular mortality.
• Extended Patient Survival: Recipients of simultaneous pancreas-kidney transplants demonstrate significantly higher overall long-term survival compared to diabetic patients receiving kidney transplantation alone.

Post-transplant recovery progresses across immediate, short-term, and long-term clinical phases. The initial inpatient phase lasts 7 to 14 days, during which surgical incisions heal, graft vascularization is verified via daily Doppler ultrasound, and immunosuppressive medications (such as tacrolimus, mycophenolate mofetil, and corticosteroids) are titrated to target blood levels. During weeks 2 through 12, patients undergo bi-weekly blood work to monitor renal function, pancreatic enzymes (amylase and lipase), blood glucose, and therapeutic drug levels. Strenuous physical activity, heavy lifting (>10 pounds), and driving are restricted for 6 to 8 weeks. Long-term recovery spans years of routine maintenance, requiring strict compliance with anti-rejection regimens, annual cardiovascular screening, routine dermatological examinations due to skin cancer risks associated with immunosuppression, and scheduled clinic follow-ups every 3 to 6 months.

Pancreas transplantation is indicated for specific severe metabolic and renal conditions associated with pancreatic endocrine insufficiency:

• Type 1 Diabetes Mellitus: Severe autoimmune destruction of insulin-producing beta cells causing absolute insulin deficiency.
• Brittle Diabetes: Extreme glycemic volatility characterized by unpredictable, severe spikes and drops in blood sugar despite optimized insulin regimens.
• Severe Hypoglycemia Unawareness: Inability to recognize falling blood glucose levels, leading to sudden neuroglycopenia, seizures, or loss of consciousness.
• Diabetic Nephropathy / End-Stage Renal Disease (ESRD): Severe kidney damage caused by chronic hyperglycemia, requiring combined kidney-pancreas transplantation.
• Pancreatogenic (Type 3c) Diabetes: Select cases of severe exocrine and endocrine pancreatic failure secondary to total pancreatectomy or chronic pancreatitis.

Pre-procedure preparation involves a rigorous multidisciplinary evaluation. Diagnostic testing includes formal cardiac evaluation (dobutamine stress echocardiography or coronary angiography), peripheral vascular duplex ultrasound, panel reactive antibody (PRA) testing, and human leukocyte antigen (HLA) typing. Viral screening covers cytomegalovirus (CMV), Epstein-Barr virus (EBV), HIV, and hepatitis B and C. Candidates undergo dental clearance to eliminate potential occult infectious sources, as well as formal psychiatric and financial evaluations. Once listed on the national donor registry (such as UNOS/OPTN), patients must maintain continuous operational readiness, remain reachable by phone 24/7, fast immediately upon receiving notification of a potential organ donor, and report to the transplant center without delay.

Complications after pancreas transplantation are categorized by severity. Early surgical complications include graft vascular thrombosis (blood clots in the donor artery or vein, occurring in 5–10% of cases and often necessitating immediate graft removal), intra-abdominal hemorrhage, surgical site infections, and pancreatic exocrine leaks resulting in intra-abdominal abscesses or fluid collections (pancreatic pseudocysts). Medical complications include acute cellular or antibody-mediated organ rejection (which occurs in 10–20% of recipients during the first year and requires pulsed steroid therapy or anti-thymocyte globulin), dynamic pancreatitis of the graft, and urinary tract complications (if bladder drainage is used). Long-term immunosuppression risks include secondary opportunistic infections (CMV, Pneumocystis jirovecii, fungal infections), nephrotoxicity from calcineurin inhibitors, new-onset diabetes after transplantation (NODAT), post-transplant lymphoproliferative disorder (PTLD), and non-melanoma skin cancers.

The clinical journey of a pancreas transplant recipient begins with a comprehensive pre-transplant evaluation, including cardiovascular risk assessment, immunological profiling, and metabolic testing. Once cleared, the candidate is placed on the national organ waitlist. When a suitable deceased donor organ becomes available, the patient is admitted for immediate surgical implantation, which typically lasts three to six hours. Post-operatively, the patient spends several days in an intensive care unit for close microvascular monitoring and glycemic tracking, followed by an inpatient stay of seven to fourteen days. Recovery requires lifelong immunosuppressive therapy, frequent outpatient laboratory monitoring, protocol graft biopsies, and structured follow-up visits to ensure graft survival and prevent organ rejection.